Quick Answer
vTv Therapeutics Inc. reported Research And Development Expense of $17.86 million for the year ending 2025.
- vTv Therapeutics Inc. showed an increase of +54.7% in Research And Development Expense from 2024 to 2025.
- This data is from vTv Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), vTv Therapeutics Inc.'s Research And Development Expense has declined by 19.9%.
- Historical annual values: Fiscal year 2025: $17.86 million | Fiscal year 2024: $11.55 million | Fiscal year 2023: $13.60 million | Fiscal year 2022: $12.36 million | Fiscal year 2021: $13.32 million | Fiscal year 2020: $11.02 million | Fiscal year 2019: $15.12 million | Fiscal year 2018: $23.04 million | Fiscal year 2017: $39.64 million | Fiscal year 2016: $44.95 million | Fiscal year 2015: $27.24 million | Fiscal year 2014: $17.38 million | Fiscal year 2013: $22.29 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: